27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In this large longitudinal investigation of generally healthy individuals Mediterranean diet was not found to be protective of cognitive decline. 1 key finding →
Design: longitudinal study Participants: 1,528 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Considering the high risk for individuals with amnestic Mild Cognitive Impairment (A-MCI) to progress towards Alzheimer's disease (AD), we investigated the efficacy of a non-pharmacological intervention, that is, cognitive training that could reduce cognitive difficulties and delay the cognitive decline. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
High adherence to the MIND diet was associated with a slower rate of cognitive decline after stroke. 2 key findings →
Design: cohort study Participants: 106 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Experimental studies on cognitive training have suggested that the effects of experience are narrow in augmenting or maintaining cognitive abilities, while correlational studies report a wide range of benefits of an engaged lifestyle, including increased longevity, resistance to dementia, and enhanced cognitive flexibility. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dietary patterns characterized by the aMED, HEI-2010, AHEI-2010, or DASH dietary score were not associated with cognitive decline in older women. 5 key findings →
Design: cohort study Participants: 6,425 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The ultimate goal of cognitive enhancement as an intervention for age-related cognitive decline is transfer to everyday cognitive functioning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings suggest that an adapted Mediterranean diet or a wheat-based, diverse diet with similar components may reduce the rate of cognitive decline in later life in the Chinese population. 5 key findings →
Design: cohort study Participants: 1,650 Evidence: moderate
Full summary, score breakdown and related studies → Original source
MCI classification guidelines should allow for functional changes in MCI, and clinicians should monitor for such changes. 2 key findings →
Design: longitudinal study Participants: 2,358 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive rehabilitation for mild cognitive impairment (MCI) and early Alzheimer's disease is readily available to the geriatric population. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
MET-FINGER aims to test a FINGER 2.0 multimodal intervention, combining an updated FINGER multidomain lifestyle intervention with metformin, where appropriate, in an APOE ε4-enriched population of older adults (60-79 years) at increased risk of dementia. 2 key findings →
Participants: 600 Evidence: high
Full summary, score breakdown and related studies → Original source
Recent demographic trends indicate that older people appear to be one of the fastest growing population groups worldwide. 2 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
Healthy lifestyles are promising targets for prevention of cognitive aging, yet the optimal time windows for interventions remain unclear. 2 key findings →
Design: case-control study Participants: 1,496 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The results indicate that cognitive difficulties in memory and speed may occur prior to a HF diagnosis, while those with HF may experience steeper declines in reasoning as measured by word series test. 2 key findings →
Design: longitudinal study Participants: 2,790 Evidence: moderate
Full summary, score breakdown and related studies → Original source
APPLE-Tree has a high probability of being cost-effective for a 1-point NTB gain, a difference previously associated with a three-fold reduction in 5-year dementia risk. 3 key findings →
Design: RCT Participants: 746 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 4413 individuals (mean [SD] age, 71.27 [4.66] years, 2617 women [59.3%]), mean Aβ-PET was elevated in individuals with history of memory impairment in both parents (n = 455; mean [SD] standardized uptake value ratio [SUVR] = 1.12 [0.19]; Wilcoxon P = 1.1 × 10-5) and in those with only maternal history (n = 1772; mean [SD] SUVR = 1.10 [0.19]; Wilcoxon P = 2.70 × 10-5) compared with those with only paternal history (n = 632; mean [SD] SUVR = 1.08 [0.18]; Wilcoxon P = 1.1 × 10-5) or no family history (n = 1554; mean [SD] SUVR = 1.08 [0.19]; Wilcoxon P = 1.1 × 10-5). 3 key findings →
Design: cross-sectional Participants: 455 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study shows that Hcy levels could modify the association between red blood cell n-3 PUFA and executive function. 2 key findings →
Participants: 1,680 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Intentional weight loss through diet was associated with cognitive improvement in patients with MCI. 4 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A decade has passed since we published a comprehensive review in this journal addressing the topic of promoting successful cognitive aging, making this a good time to take stock of the field. 5 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Preclinical AD is associated with rest-activity rhythm fragmentation, independent of age or sex. 5 key findings →
Design: cross-sectional Participants: 205 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Although APOE ε4 carriers are at high risk for cognitive decline, our findings suggest possible intervention targets, including the enhancement of cognitive reserve and improvement of other psychosocial and health factors, to promote cognitive resilience among black and white APOE ε4 carriers. 5 key findings →
Design: prospective cohort Participants: 2,487 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is independently associated with lower scores on tests of memory and executive function. 5 key findings →
Design: cross-sectional Participants: 347 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MCI is highly prevalent in older adults with profound hearing loss. 3 key findings →
Design: longitudinal study Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We aimed to characterise the brain structure of superagers and identify demographic, lifestyle, and clinical factors associated with this phenotype. 4 key findings →
Design: longitudinal study Participants: 64 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is associated with poor cognitive performance and incident dementia and may contribute to cognitive decline. 5 key findings →
Participants: 164,770 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Public Psychiatric Hospital Rekem, Belgium. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
10 of the 1,130 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →